Trial Outcomes & Findings for SCS Research Study (NCT NCT03763708)
NCT ID: NCT03763708
Last Updated: 2024-12-31
Results Overview
To characterize the effect of different programmed settings on pain relief. The NPRS will be recorded once or daily over a period of time, where the subjects will rate their pain on a 11-point numeric rating scale of 0 to 10, with 0 representing 'No Pain' and 10 representing 'Worst pain imaginable'. The average overall NPRS pain score prior to the scheduled visit will be used for analysis.
Recruitment status
TERMINATED
Study phase
NA
Target enrollment
100 participants
Primary outcome timeframe
Up to 5 months
Results posted on
2024-12-31
Participant Flow
Some subjects participated in more than one cohort during the lifecycle of the study.
Participant milestones
| Measure |
Cohort 1: Low Energy - Continuous
Subjects will be programmed to a specific frequency with a long pulse width at various amplitudes
Spinal Cord Stimulation: Programming
|
Cohort 2: Interleaving
Determine effects of delivering ping pulses combined with governed pulses while using separate sets of electrodes
Spinal Cord Stimulation: Programming
|
Cohort 3: Cycling Evolve
Subjects will be programmed to high dose (HD) stimulation with various cycling parameters
Spinal Cord Stimulation: Programming
|
Cohort 4: Low Energy Cycling 1
Effects of decreased pulse widths with increased frequency - with and without cycling parameters
Spinal Cord Stimulation: Programming
|
Cohort 5: Low Energy Cycling 2
Effects of decreased pulse widths with increased frequency - with and without cycling parameters (different pulse widths and frequencies than Cohort 4)
Spinal Cord Stimulation: Programming
|
Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS)
Effects of decreased frequency and therapy cycling parameters
Spinal Cord Stimulation: Programming
|
Cohort 7: Super Cycle
Effects of longer cycle duration
Spinal Cord Stimulation: Programming
|
Cohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS)
Effects of integrating Neuro Sense into DTM programming
Spinal Cord Stimulation: Programming
|
Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow
Characteristics of vital signs in DPN participants
Spinal Cord Stimulation: Programming
|
|---|---|---|---|---|---|---|---|---|---|
|
Cohort 1: Low Energy -Continuous
STARTED
|
15
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Cohort 1: Low Energy -Continuous
COMPLETED
|
11
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Cohort 1: Low Energy -Continuous
NOT COMPLETED
|
4
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Cohort 2: Interleaving
STARTED
|
0
|
10
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Cohort 2: Interleaving
COMPLETED
|
0
|
10
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Cohort 2: Interleaving
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Cohort 3: Cycling Evolve
STARTED
|
0
|
0
|
4
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Cohort 3: Cycling Evolve
COMPLETED
|
0
|
0
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Cohort 3: Cycling Evolve
NOT COMPLETED
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Cohort 4: Low Energy Cycling 1
STARTED
|
0
|
0
|
0
|
15
|
0
|
0
|
0
|
0
|
0
|
|
Cohort 4: Low Energy Cycling 1
COMPLETED
|
0
|
0
|
0
|
13
|
0
|
0
|
0
|
0
|
0
|
|
Cohort 4: Low Energy Cycling 1
NOT COMPLETED
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
0
|
|
Cohort 5: Low Energy Cycling 2
STARTED
|
0
|
0
|
0
|
0
|
15
|
0
|
0
|
0
|
0
|
|
Cohort 5: Low Energy Cycling 2
COMPLETED
|
0
|
0
|
0
|
0
|
13
|
0
|
0
|
0
|
0
|
|
Cohort 5: Low Energy Cycling 2
NOT COMPLETED
|
0
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
|
Cohort 6: DTM-LE SCS
STARTED
|
0
|
0
|
0
|
0
|
0
|
22
|
0
|
0
|
0
|
|
Cohort 6: DTM-LE SCS
COMPLETED
|
0
|
0
|
0
|
0
|
0
|
20
|
0
|
0
|
0
|
|
Cohort 6: DTM-LE SCS
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
|
Cohort 7: Super Cycle
STARTED
|
0
|
0
|
0
|
0
|
0
|
0
|
17
|
0
|
0
|
|
Cohort 7: Super Cycle
COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
6
|
0
|
0
|
|
Cohort 7: Super Cycle
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
11
|
0
|
0
|
|
Cohort 8: DTM for NS
STARTED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
0
|
|
Cohort 8: DTM for NS
COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
0
|
|
Cohort 8: DTM for NS
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Cohort 9: DPN Flow
STARTED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
11
|
|
Cohort 9: DPN Flow
COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
10
|
|
Cohort 9: DPN Flow
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
Reasons for withdrawal
| Measure |
Cohort 1: Low Energy - Continuous
Subjects will be programmed to a specific frequency with a long pulse width at various amplitudes
Spinal Cord Stimulation: Programming
|
Cohort 2: Interleaving
Determine effects of delivering ping pulses combined with governed pulses while using separate sets of electrodes
Spinal Cord Stimulation: Programming
|
Cohort 3: Cycling Evolve
Subjects will be programmed to high dose (HD) stimulation with various cycling parameters
Spinal Cord Stimulation: Programming
|
Cohort 4: Low Energy Cycling 1
Effects of decreased pulse widths with increased frequency - with and without cycling parameters
Spinal Cord Stimulation: Programming
|
Cohort 5: Low Energy Cycling 2
Effects of decreased pulse widths with increased frequency - with and without cycling parameters (different pulse widths and frequencies than Cohort 4)
Spinal Cord Stimulation: Programming
|
Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS)
Effects of decreased frequency and therapy cycling parameters
Spinal Cord Stimulation: Programming
|
Cohort 7: Super Cycle
Effects of longer cycle duration
Spinal Cord Stimulation: Programming
|
Cohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS)
Effects of integrating Neuro Sense into DTM programming
Spinal Cord Stimulation: Programming
|
Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow
Characteristics of vital signs in DPN participants
Spinal Cord Stimulation: Programming
|
|---|---|---|---|---|---|---|---|---|---|
|
Cohort 1: Low Energy -Continuous
Withdrawal by Subject
|
4
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Cohort 3: Cycling Evolve
Withdrawal by Subject
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Cohort 4: Low Energy Cycling 1
Withdrawal by Subject
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
0
|
|
Cohort 5: Low Energy Cycling 2
Withdrawal by Subject
|
0
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
|
Cohort 6: DTM-LE SCS
Withdrawal by Subject
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
|
Cohort 7: Super Cycle
Withdrawal by Subject
|
0
|
0
|
0
|
0
|
0
|
0
|
9
|
0
|
0
|
|
Cohort 7: Super Cycle
Adverse Event
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
Cohort 7: Super Cycle
Screen Failure
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
Cohort 9: DPN Flow
Screen Failure
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
Baseline Characteristics
Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
Baseline characteristics by cohort
| Measure |
Cohort 1: Low Energy - Continuous
n=15 Participants
Subjects will be programmed to a specific frequency with a long pulse width at various amplitudes
Spinal Cord Stimulation: Programming
|
Cohort 2: Interleaving
n=10 Participants
Determine effects of delivering ping pulses combined with governed pulses while using separate sets of electrodes
Spinal Cord Stimulation: Programming
|
Cohort 3: Cycling Evolve
n=4 Participants
Subjects will be programmed to high dose (HD) stimulation with various cycling parameters
Spinal Cord Stimulation: Programming
|
Cohort 4: Low Energy Cycling 1
n=15 Participants
Effects of decreased pulse widths with increased frequency - with and without cycling parameters
Spinal Cord Stimulation: Programming
|
Cohort 5: Low Energy Cycling 2
n=15 Participants
Effects of decreased pulse widths with increased frequency - with and without cycling parameters (different pulse widths and frequencies than Cohort 4)
Spinal Cord Stimulation: Programming
|
Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS)
n=22 Participants
Effects of decreased frequency and therapy cycling parameters
Spinal Cord Stimulation: Programming
|
Cohort 7: Super Cycle
n=17 Participants
Effects of longer cycle duration
Spinal Cord Stimulation: Programming
|
Cohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS)
n=4 Participants
Effects of integrating Neuro Sense into DTM programming
Spinal Cord Stimulation: Programming
|
Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow
n=11 Participants
Characteristics of vital signs in DPN participants
Spinal Cord Stimulation: Programming
|
Total
n=113 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Primary Indication
Cohort 5: Low Energy Cycling 2 · Epidural Fibrosis
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 5: Low Energy Cycling 2 · Failed Back Surgery Syndrome
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Age, Continuous
Cohort 1: Low Energy - Continuous
|
60.5 years
STANDARD_DEVIATION 7.9 • n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
60.5 years
STANDARD_DEVIATION 7.9 • n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Age, Continuous
Cohort 2: Interleaving
|
—
|
55.6 years
STANDARD_DEVIATION 9.5 • n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
55.6 years
STANDARD_DEVIATION 9.5 • n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Age, Continuous
Cohort 3: Cycling Evolve
|
—
|
—
|
59.4 years
STANDARD_DEVIATION 9.0 • n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
59.4 years
STANDARD_DEVIATION 9.0 • n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Age, Continuous
Cohort 4: Low Energy Cycling 1
|
—
|
—
|
—
|
55.0 years
STANDARD_DEVIATION 10.5 • n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
55.0 years
STANDARD_DEVIATION 10.5 • n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Age, Continuous
Cohort 5: Low Energy Cycling 2
|
—
|
—
|
—
|
—
|
55.2 years
STANDARD_DEVIATION 12.3 • n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
55.2 years
STANDARD_DEVIATION 12.3 • n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Age, Continuous
Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS)
|
—
|
—
|
—
|
—
|
—
|
62.4 years
STANDARD_DEVIATION 11.4 • n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
62.4 years
STANDARD_DEVIATION 11.4 • n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Age, Continuous
Cohort 7: Super Cycle
|
—
|
—
|
—
|
—
|
—
|
—
|
64.9 years
STANDARD_DEVIATION 8.7 • n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
64.9 years
STANDARD_DEVIATION 8.7 • n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Age, Continuous
Cohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS)
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
66.25 years
STANDARD_DEVIATION 17.3 • n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
66.25 years
STANDARD_DEVIATION 17.3 • n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Age, Continuous
Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
55.9 years
STANDARD_DEVIATION 16.37 • n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
55.9 years
STANDARD_DEVIATION 16.37 • n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Sex: Female, Male
Cohort 1: Low Energy - Continuous · Female
|
8 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
8 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Sex: Female, Male
Cohort 1: Low Energy - Continuous · Male
|
7 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
7 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Sex: Female, Male
Cohort 2: Interleaving · Female
|
—
|
6 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
6 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Sex: Female, Male
Cohort 2: Interleaving · Male
|
—
|
4 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
4 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Sex: Female, Male
Cohort 3: Cycling Evolve · Female
|
—
|
—
|
2 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
2 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Sex: Female, Male
Cohort 3: Cycling Evolve · Male
|
—
|
—
|
2 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
2 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Sex: Female, Male
Cohort 4: Low Energy Cycling 1 · Female
|
—
|
—
|
—
|
5 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
5 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Sex: Female, Male
Cohort 4: Low Energy Cycling 1 · Male
|
—
|
—
|
—
|
10 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
10 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Sex: Female, Male
Cohort 5: Low Energy Cycling 2 · Female
|
—
|
—
|
—
|
—
|
7 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
7 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Sex: Female, Male
Cohort 5: Low Energy Cycling 2 · Male
|
—
|
—
|
—
|
—
|
8 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
8 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Sex: Female, Male
Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS) · Female
|
—
|
—
|
—
|
—
|
—
|
13 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
13 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Sex: Female, Male
Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS) · Male
|
—
|
—
|
—
|
—
|
—
|
9 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
9 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Sex: Female, Male
Cohort 7: Super Cycle · Female
|
—
|
—
|
—
|
—
|
—
|
—
|
10 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
10 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Sex: Female, Male
Cohort 7: Super Cycle · Male
|
—
|
—
|
—
|
—
|
—
|
—
|
7 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
7 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Sex: Female, Male
Cohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS) · Female
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
1 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
1 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Sex: Female, Male
Cohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS) · Male
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
3 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
3 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Sex: Female, Male
Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow · Female
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
6 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
6 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Sex: Female, Male
Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow · Male
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
5 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
5 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Ethnicity (NIH/OMB)
Cohort 1: Low Energy - Continuous · Hispanic or Latino
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Ethnicity (NIH/OMB)
Cohort 1: Low Energy - Continuous · Not Hispanic or Latino
|
15 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
15 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Ethnicity (NIH/OMB)
Cohort 1: Low Energy - Continuous · Unknown or Not Reported
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Ethnicity (NIH/OMB)
Cohort 2: Interleaving · Hispanic or Latino
|
—
|
0 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Ethnicity (NIH/OMB)
Cohort 2: Interleaving · Not Hispanic or Latino
|
—
|
10 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
10 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Ethnicity (NIH/OMB)
Cohort 2: Interleaving · Unknown or Not Reported
|
—
|
0 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Ethnicity (NIH/OMB)
Cohort 3: Cycling Evolve · Hispanic or Latino
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Ethnicity (NIH/OMB)
Cohort 3: Cycling Evolve · Not Hispanic or Latino
|
—
|
—
|
4 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
4 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Ethnicity (NIH/OMB)
Cohort 3: Cycling Evolve · Unknown or Not Reported
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Ethnicity (NIH/OMB)
Cohort 4: Low Energy Cycling 1 · Hispanic or Latino
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Ethnicity (NIH/OMB)
Cohort 4: Low Energy Cycling 1 · Not Hispanic or Latino
|
—
|
—
|
—
|
13 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
13 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Ethnicity (NIH/OMB)
Cohort 4: Low Energy Cycling 1 · Unknown or Not Reported
|
—
|
—
|
—
|
2 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
2 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Ethnicity (NIH/OMB)
Cohort 5: Low Energy Cycling 2 · Hispanic or Latino
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Ethnicity (NIH/OMB)
Cohort 5: Low Energy Cycling 2 · Not Hispanic or Latino
|
—
|
—
|
—
|
—
|
15 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
15 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Ethnicity (NIH/OMB)
Cohort 5: Low Energy Cycling 2 · Unknown or Not Reported
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Ethnicity (NIH/OMB)
Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS) · Hispanic or Latino
|
—
|
—
|
—
|
—
|
—
|
1 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
1 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Ethnicity (NIH/OMB)
Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS) · Not Hispanic or Latino
|
—
|
—
|
—
|
—
|
—
|
21 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
21 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Ethnicity (NIH/OMB)
Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS) · Unknown or Not Reported
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
0 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Ethnicity (NIH/OMB)
Cohort 7: Super Cycle · Hispanic or Latino
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
0 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Ethnicity (NIH/OMB)
Cohort 7: Super Cycle · Not Hispanic or Latino
|
—
|
—
|
—
|
—
|
—
|
—
|
17 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
17 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Ethnicity (NIH/OMB)
Cohort 7: Super Cycle · Unknown or Not Reported
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
0 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Ethnicity (NIH/OMB)
Cohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS) · Hispanic or Latino
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Ethnicity (NIH/OMB)
Cohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS) · Not Hispanic or Latino
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
4 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
4 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Ethnicity (NIH/OMB)
Cohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS) · Unknown or Not Reported
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Ethnicity (NIH/OMB)
Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow · Hispanic or Latino
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
0 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Ethnicity (NIH/OMB)
Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow · Not Hispanic or Latino
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
11 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
11 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Ethnicity (NIH/OMB)
Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow · Unknown or Not Reported
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
0 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 1: Low Energy - Continuous · American Indian or Alaska Native
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 1: Low Energy - Continuous · Asian
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 1: Low Energy - Continuous · Black or African American
|
1 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
1 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 1: Low Energy - Continuous · Native Hawaiian or Other Pacific Islander
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 1: Low Energy - Continuous · White
|
14 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
14 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 1: Low Energy - Continuous · Other
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 2: Interleaving · American Indian or Alaska Native
|
—
|
0 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 2: Interleaving · Asian
|
—
|
0 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 2: Interleaving · Black or African American
|
—
|
1 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
1 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 2: Interleaving · Native Hawaiian or Other Pacific Islander
|
—
|
0 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 2: Interleaving · White
|
—
|
9 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
9 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 2: Interleaving · Other
|
—
|
0 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 3: Cycling Evolve · American Indian or Alaska Native
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 3: Cycling Evolve · Asian
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 3: Cycling Evolve · Black or African American
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 3: Cycling Evolve · Native Hawaiian or Other Pacific Islander
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 3: Cycling Evolve · White
|
—
|
—
|
4 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
4 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 3: Cycling Evolve · Other
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 4: Low Energy Cycling 1 · American Indian or Alaska Native
|
—
|
—
|
—
|
1 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
1 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 4: Low Energy Cycling 1 · Asian
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 4: Low Energy Cycling 1 · Black or African American
|
—
|
—
|
—
|
3 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
3 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 4: Low Energy Cycling 1 · Native Hawaiian or Other Pacific Islander
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 4: Low Energy Cycling 1 · White
|
—
|
—
|
—
|
11 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
11 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 4: Low Energy Cycling 1 · Other
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 5: Low Energy Cycling 2 · American Indian or Alaska Native
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 5: Low Energy Cycling 2 · Asian
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 5: Low Energy Cycling 2 · Black or African American
|
—
|
—
|
—
|
—
|
1 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
1 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 5: Low Energy Cycling 2 · Native Hawaiian or Other Pacific Islander
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 5: Low Energy Cycling 2 · White
|
—
|
—
|
—
|
—
|
14 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
14 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 5: Low Energy Cycling 2 · Other
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS) · American Indian or Alaska Native
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
0 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS) · Asian
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
0 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS) · Black or African American
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
0 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS) · Native Hawaiian or Other Pacific Islander
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
0 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS) · White
|
—
|
—
|
—
|
—
|
—
|
22 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
22 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS) · Other
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
0 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 7: Super Cycle · American Indian or Alaska Native
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
0 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 7: Super Cycle · Asian
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
0 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 7: Super Cycle · Black or African American
|
—
|
—
|
—
|
—
|
—
|
—
|
1 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
1 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 7: Super Cycle · Native Hawaiian or Other Pacific Islander
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
0 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 7: Super Cycle · White
|
—
|
—
|
—
|
—
|
—
|
—
|
16 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
16 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 7: Super Cycle · Other
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
0 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS) · American Indian or Alaska Native
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS) · Asian
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS) · Black or African American
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS) · Native Hawaiian or Other Pacific Islander
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS) · White
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
4 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
4 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS) · Other
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow · American Indian or Alaska Native
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
0 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow · Asian
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
0 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow · Black or African American
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
1 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
1 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow · Native Hawaiian or Other Pacific Islander
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
0 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow · White
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
10 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
10 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Race/Ethnicity, Customized
Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow · Other
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
0 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Region of Enrollment
United States
|
15 participants
n=15 Participants
|
10 participants
n=10 Participants
|
4 participants
n=4 Participants
|
15 participants
n=15 Participants
|
15 participants
n=15 Participants
|
22 participants
n=22 Participants
|
17 participants
n=17 Participants
|
4 participants
n=4 Participants
|
11 participants
n=11 Participants
|
113 participants
n=113 Participants
|
|
Primary Indication
Cohort 1: Low Energy - Continuous · Arachnoiditis
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 1: Low Energy - Continuous · Complex Regional Pain Syndrome
|
2 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
2 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 1: Low Energy - Continuous · Degenerative Disc Disease
|
1 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
1 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 1: Low Energy - Continuous · Epidural Fibrosis
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 1: Low Energy - Continuous · Failed Back Surgery Syndrome
|
3 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
3 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 1: Low Energy - Continuous · Multiple Back Operations
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 1: Low Energy - Continuous · Peripheral Causalgia
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 1: Low Energy - Continuous · Postlaminectomy Pain
|
6 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
6 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 1: Low Energy - Continuous · Radicular Pain Syndrome
|
2 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
2 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 1: Low Energy - Continuous · Unsuccessful Disc Surgery
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 1: Low Energy - Continuous · Other
|
1 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
1 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 2: Interleaving · Arachnoiditis
|
—
|
0 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 2: Interleaving · Complex Regional Pain Syndrome
|
—
|
0 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 2: Interleaving · Degenerative Disc Disease
|
—
|
0 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 2: Interleaving · Epidural Fibrosis
|
—
|
0 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 2: Interleaving · Failed Back Surgery Syndrome
|
—
|
0 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 2: Interleaving · Multiple Back Operations
|
—
|
0 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 2: Interleaving · Peripheral Causalgia
|
—
|
0 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 2: Interleaving · Postlaminectomy Pain
|
—
|
5 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
5 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 2: Interleaving · Radicular Pain Syndrome
|
—
|
4 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
4 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 2: Interleaving · Unsuccessful Disc Surgery
|
—
|
0 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 2: Interleaving · Other
|
—
|
1 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
1 Participants
n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 3: Cycling Evolve · Arachnoiditis
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 3: Cycling Evolve · Complex Regional Pain Syndrome
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 3: Cycling Evolve · Degenerative Disc Disease
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 3: Cycling Evolve · Epidural Fibrosis
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 3: Cycling Evolve · Failed Back Surgery Syndrome
|
—
|
—
|
1 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
1 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 3: Cycling Evolve · Multiple Back Operations
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 3: Cycling Evolve · Peripheral Causalgia
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 3: Cycling Evolve · Postlaminectomy Pain
|
—
|
—
|
3 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
3 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 3: Cycling Evolve · Radicular Pain Syndrome
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 3: Cycling Evolve · Unsuccessful Disc Surgery
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 3: Cycling Evolve · Other
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 4: Low Energy Cycling 1 · Arachnoiditis
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 4: Low Energy Cycling 1 · Complex Regional Pain Syndrome
|
—
|
—
|
—
|
1 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
1 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 4: Low Energy Cycling 1 · Degenerative Disc Disease
|
—
|
—
|
—
|
3 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
3 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 4: Low Energy Cycling 1 · Epidural Fibrosis
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 4: Low Energy Cycling 1 · Failed Back Surgery Syndrome
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 4: Low Energy Cycling 1 · Multiple Back Operations
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 4: Low Energy Cycling 1 · Peripheral Causalgia
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 4: Low Energy Cycling 1 · Postlaminectomy Pain
|
—
|
—
|
—
|
9 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
9 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 4: Low Energy Cycling 1 · Radicular Pain Syndrome
|
—
|
—
|
—
|
1 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
1 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 4: Low Energy Cycling 1 · Unsuccessful Disc Surgery
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 4: Low Energy Cycling 1 · Other
|
—
|
—
|
—
|
1 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
1 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 5: Low Energy Cycling 2 · Arachnoiditis
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 5: Low Energy Cycling 2 · Complex Regional Pain Syndrome
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 5: Low Energy Cycling 2 · Degenerative Disc Disease
|
—
|
—
|
—
|
—
|
2 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
2 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 5: Low Energy Cycling 2 · Multiple Back Operations
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 5: Low Energy Cycling 2 · Peripheral Causalgia
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 5: Low Energy Cycling 2 · Postlaminectomy Pain
|
—
|
—
|
—
|
—
|
8 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
8 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 5: Low Energy Cycling 2 · Radicular Pain Syndrome
|
—
|
—
|
—
|
—
|
5 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
5 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 5: Low Energy Cycling 2 · Unsuccessful Disc Surgery
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 5: Low Energy Cycling 2 · Other
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
0 Participants
n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS) · Arachnoiditis
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
0 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS) · Complex Regional Pain Syndrome
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
0 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS) · Degenerative Disc Disease
|
—
|
—
|
—
|
—
|
—
|
2 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
2 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS) · Epidural Fibrosis
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
0 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS) · Failed Back Surgery Syndrome
|
—
|
—
|
—
|
—
|
—
|
2 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
2 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS) · Multiple Back Operations
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
0 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS) · Peripheral Causalgia
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
0 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS) · Postlaminectomy Pain
|
—
|
—
|
—
|
—
|
—
|
14 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
14 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS) · Radicular Pain Syndrome
|
—
|
—
|
—
|
—
|
—
|
4 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
4 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS) · Unsuccessful Disc Surgery
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
0 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS) · Other
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
0 Participants
n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 7: Super Cycle · Arachnoiditis
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
0 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 7: Super Cycle · Complex Regional Pain Syndrome
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
0 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 7: Super Cycle · Degenerative Disc Disease
|
—
|
—
|
—
|
—
|
—
|
—
|
1 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
1 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 7: Super Cycle · Epidural Fibrosis
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
0 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 7: Super Cycle · Failed Back Surgery Syndrome
|
—
|
—
|
—
|
—
|
—
|
—
|
2 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
2 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 7: Super Cycle · Multiple Back Operations
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
0 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 7: Super Cycle · Peripheral Causalgia
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
0 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 7: Super Cycle · Postlaminectomy Pain
|
—
|
—
|
—
|
—
|
—
|
—
|
9 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
9 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 7: Super Cycle · Radicular Pain Syndrome
|
—
|
—
|
—
|
—
|
—
|
—
|
3 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
3 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 7: Super Cycle · Unsuccessful Disc Surgery
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
0 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 7: Super Cycle · Other
|
—
|
—
|
—
|
—
|
—
|
—
|
2 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
2 Participants
n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS) · Arachnoiditis
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS) · Complex Regional Pain Syndrome
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS) · Degenerative Disc Disease
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
1 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
1 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS) · Epidural Fibrosis
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS) · Failed Back Surgery Syndrome
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
1 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
1 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS) · Multiple Back Operations
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS) · Peripheral Causalgia
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS) · Postlaminectomy Pain
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS) · Radicular Pain Syndrome
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
2 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
2 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS) · Unsuccessful Disc Surgery
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS) · Other
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
0 Participants
n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow · Arachnoiditis
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
0 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow · Complex Regional Pain Syndrome
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
2 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
2 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow · Degenerative Disc Disease
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
0 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow · Epidural Fibrosis
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
0 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow · Failed Back Surgery Syndrome
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
0 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow · Multiple Back Operations
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
0 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow · Peripheral Causalgia
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
0 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow · Postlaminectomy Pain
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
8 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
8 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow · Radicular Pain Syndrome
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
1 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
1 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow · Unsuccessful Disc Surgery
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
0 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Primary Indication
Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow · Other
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
0 Participants
n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Years Since Onset of Chronic Pain
Cohort 1: Low Energy - Continuous
|
13.7 years
STANDARD_DEVIATION 9.8 • n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
13.7 years
STANDARD_DEVIATION 9.8 • n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Years Since Onset of Chronic Pain
Cohort 2: Interleaving
|
—
|
21.5 years
STANDARD_DEVIATION 15.8 • n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
21.5 years
STANDARD_DEVIATION 15.8 • n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Years Since Onset of Chronic Pain
Cohort 3: Cycling Evolve
|
—
|
—
|
27.0 years
STANDARD_DEVIATION 18.7 • n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
27.0 years
STANDARD_DEVIATION 18.7 • n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Years Since Onset of Chronic Pain
Cohort 4: Low Energy Cycling 1
|
—
|
—
|
—
|
20.7 years
STANDARD_DEVIATION 16.4 • n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
20.7 years
STANDARD_DEVIATION 16.4 • n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Years Since Onset of Chronic Pain
Cohort 5: Low Energy Cycling 2
|
—
|
—
|
—
|
—
|
16.5 years
STANDARD_DEVIATION 8.4 • n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
16.5 years
STANDARD_DEVIATION 8.4 • n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Years Since Onset of Chronic Pain
Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS)
|
—
|
—
|
—
|
—
|
—
|
20.6 years
STANDARD_DEVIATION 12.4 • n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
20.6 years
STANDARD_DEVIATION 12.4 • n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Years Since Onset of Chronic Pain
Cohort 7: Super Cycle
|
—
|
—
|
—
|
—
|
—
|
—
|
9.5 years
STANDARD_DEVIATION 9.1 • n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
9.5 years
STANDARD_DEVIATION 9.1 • n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Years Since Onset of Chronic Pain
Cohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS)
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
4.25 years
STANDARD_DEVIATION 2.6 • n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
4.25 years
STANDARD_DEVIATION 2.6 • n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Years Since Onset of Chronic Pain
Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
17.8 years
STANDARD_DEVIATION 17.17 • n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
17.8 years
STANDARD_DEVIATION 17.17 • n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Days Since Implant to Enrollment
|
—
|
—
|
—
|
—
|
—
|
—
|
13.9 days
STANDARD_DEVIATION 3.8 • n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
13.9 days
STANDARD_DEVIATION 3.8 • n=17 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Years Since Implant to Enrollment
Cohort 1: Low Energy - Continuous
|
0.9 years
STANDARD_DEVIATION 1.0 • n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0.9 years
STANDARD_DEVIATION 1.0 • n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Years Since Implant to Enrollment
Cohort 2: Interleaving
|
—
|
0.8 years
STANDARD_DEVIATION 0.4 • n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0.8 years
STANDARD_DEVIATION 0.4 • n=10 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Years Since Implant to Enrollment
Cohort 3: Cycling Evolve
|
—
|
—
|
1.1 years
STANDARD_DEVIATION 0.5 • n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
—
|
1.1 years
STANDARD_DEVIATION 0.5 • n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Years Since Implant to Enrollment
Cohort 4: Low Energy Cycling 1
|
—
|
—
|
—
|
1.1 years
STANDARD_DEVIATION 0.5 • n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
—
|
1.1 years
STANDARD_DEVIATION 0.5 • n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Years Since Implant to Enrollment
Cohort 5: Low Energy Cycling 2
|
—
|
—
|
—
|
—
|
1.1 years
STANDARD_DEVIATION 0.5 • n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
—
|
1.1 years
STANDARD_DEVIATION 0.5 • n=15 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Years Since Implant to Enrollment
Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS)
|
—
|
—
|
—
|
—
|
—
|
1.6 years
STANDARD_DEVIATION 1.0 • n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
—
|
—
|
1.6 years
STANDARD_DEVIATION 1.0 • n=22 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Years Since Implant to Enrollment
Cohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS)
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0.83 years
STANDARD_DEVIATION 0.4 • n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
—
|
0.83 years
STANDARD_DEVIATION 0.4 • n=4 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
|
Years Since Implant to Enrollment
Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
4.5 years
STANDARD_DEVIATION 4.37 • n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
4.5 years
STANDARD_DEVIATION 4.37 • n=11 Participants • Some participants joined a new cohort once their current cohort was completed, and they met the new cohort guidelines. Therefore, there were participants who ended up in more than one of the 9 cohorts. There were a total of 100 unique participants in this study.
|
PRIMARY outcome
Timeframe: Up to 5 monthsPopulation: Number analyzed refers to patients with measure available.
To characterize the effect of different programmed settings on pain relief. The NPRS will be recorded once or daily over a period of time, where the subjects will rate their pain on a 11-point numeric rating scale of 0 to 10, with 0 representing 'No Pain' and 10 representing 'Worst pain imaginable'. The average overall NPRS pain score prior to the scheduled visit will be used for analysis.
Outcome measures
| Measure |
Cohort 1: Low Energy - Continuous Initial
n=14 Participants
Subjects will be programmed to a specific frequency with a long pulse width at various amplitudes
Spinal Cord Stimulation: Programming
|
|---|---|
|
Numeric Pain Rating Scale (NPRS) - Cohort 1
Enrollment
|
5.2 score on a scale
Standard Deviation 2.5
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 1
Comfortable amplitude (Period 1)
|
4.9 score on a scale
Standard Deviation 2.3
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 1
80% comfortable amplitude (Period 2)
|
5.1 score on a scale
Standard Deviation 2.3
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 1
60% comfortable amplitude (Period 3)
|
4.9 score on a scale
Standard Deviation 2.1
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 1
40% comfortable amplitude (Period 4)
|
4.6 score on a scale
Standard Deviation 2.1
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 1
20% comfortable amplitude (Period 5)
|
4.7 score on a scale
Standard Deviation 2.0
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 1
0 mA/V (Period 6)
|
4.7 score on a scale
Standard Deviation 1.9
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 1
Comfortable amplitude with 25% duty cycle (Period 7)
|
4.3 score on a scale
Standard Deviation 2.3
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 1
The "best" amplitude and cycling enabling 5 years on a PC (Period 8)
|
4.7 score on a scale
Standard Deviation 1.9
|
PRIMARY outcome
Timeframe: Up to 2 monthsTo characterize the effect of different programmed settings on pain relief. The NPRS will be recorded once or daily over a period of time, where the subjects will rate their pain on a 11-point numeric rating scale of 0 to 10, with 0 representing 'No Pain' and 10 representing 'Worst pain imaginable'. The average overall NPRS pain score prior to the scheduled visit will be used for analysis.
Outcome measures
| Measure |
Cohort 1: Low Energy - Continuous Initial
n=9 Participants
Subjects will be programmed to a specific frequency with a long pulse width at various amplitudes
Spinal Cord Stimulation: Programming
|
|---|---|
|
Numeric Pain Rating Scale (NPRS) - Cohort 2
Enrollment
|
4.6 score on a scale
Standard Deviation 2.46
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 2
Follow-up (HD)
|
4.3 score on a scale
Standard Deviation 2.48
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 2
Follow-up (LD)
|
5.5 score on a scale
Standard Deviation 1.33
|
PRIMARY outcome
Timeframe: Up to 3 monthsPopulation: Number analyzed refers to patients with measure available.
To characterize the effect of different programmed settings on pain relief. The NPRS will be recorded once or daily over a period of time, where the subjects will rate their pain on a 11-point numeric rating scale of 0 to 10, with 0 representing 'No Pain' and 10 representing 'Worst pain imaginable'. The average overall NPRS pain score prior to the scheduled visit will be used for analysis.
Outcome measures
| Measure |
Cohort 1: Low Energy - Continuous Initial
n=4 Participants
Subjects will be programmed to a specific frequency with a long pulse width at various amplitudes
Spinal Cord Stimulation: Programming
|
|---|---|
|
Numeric Pain Rating Scale (NPRS) - Cohort 3
Enrollment
|
4.0 score on a scale
Standard Deviation 2.6
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 3
Follow Up 1 (Came in at Cycling Off)
|
3.9 score on a scale
Standard Deviation 2.4
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 3
Follow Up 2 (Came in at Cycling ON)
|
4.9 score on a scale
Standard Deviation 2.2
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 3
Follow Up 3 (Came in at Cycling ON)
|
4.5 score on a scale
Standard Deviation 2.1
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 3
Follow Up 4 (Came in at Cycling ON)
|
4.7 score on a scale
Standard Deviation 2.5
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 3
Follow Up 5 (Came in at Cycling ON)
|
4.2 score on a scale
Standard Deviation 2.4
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 3
Final Study Visit (Came in at Cycling ON)
|
3.2 score on a scale
Standard Deviation 2.2
|
PRIMARY outcome
Timeframe: Up to 5 monthsPopulation: Number analyzed refers to patients with measure available.
To characterize the effect of different programmed settings on pain relief. The NPRS will be recorded once or daily over a period of time, where the subjects will rate their pain on a 11-point numeric rating scale of 0 to 10, with 0 representing 'No Pain' and 10 representing 'Worst pain imaginable'. The average overall NPRS pain score prior to the scheduled visit will be used for analysis.
Outcome measures
| Measure |
Cohort 1: Low Energy - Continuous Initial
n=15 Participants
Subjects will be programmed to a specific frequency with a long pulse width at various amplitudes
Spinal Cord Stimulation: Programming
|
|---|---|
|
Numeric Pain Rating Scale (NPRS) - Cohort 4
Enrollment
|
3.9 score on a scale
Standard Deviation 3.0
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 4
Low Energy 1, cycling off (Period 1)
|
4.9 score on a scale
Standard Deviation 2.4
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 4
Low Energy 1, cycling ON (Period 2)
|
5.1 score on a scale
Standard Deviation 2.0
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 4
Low Energy 1, cycling ON (Period 3)
|
5.6 score on a scale
Standard Deviation 2.1
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 4
Low Energy 2, cycling off (Period 4)
|
4.7 score on a scale
Standard Deviation 2.3
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 4
Low Energy 2, cycling ON (Period 5)
|
4.9 score on a scale
Standard Deviation 2.3
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 4
Low Energy 2, cycling ON (Period 6)
|
5.1 score on a scale
Standard Deviation 2.4
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 4
Low Energy 2, cycling ON (Period 7)
|
5.3 score on a scale
Standard Deviation 2.4
|
PRIMARY outcome
Timeframe: Up to 5 monthsPopulation: Number analyzed refers to patients with measure available.
To characterize the effect of different programmed settings on pain relief. The NPRS will be recorded once or daily over a period of time, where the subjects will rate their pain on a 11-point numeric rating scale of 0 to 10, with 0 representing 'No Pain' and 10 representing 'Worst pain imaginable'. The average overall NPRS pain score prior to the scheduled visit will be used for analysis.
Outcome measures
| Measure |
Cohort 1: Low Energy - Continuous Initial
n=15 Participants
Subjects will be programmed to a specific frequency with a long pulse width at various amplitudes
Spinal Cord Stimulation: Programming
|
|---|---|
|
Numeric Pain Rating Scale - Cohort 5
Enrollment
|
4.8 score on a scale
Standard Deviation 2.5
|
|
Numeric Pain Rating Scale - Cohort 5
Low Energy 1, cycling off (Period 1)
|
5.0 score on a scale
Standard Deviation 1.9
|
|
Numeric Pain Rating Scale - Cohort 5
Low Energy 1, cycling ON (Period 2)
|
5.0 score on a scale
Standard Deviation 2.0
|
|
Numeric Pain Rating Scale - Cohort 5
Low Energy 1, cycling ON (Period 3)
|
5.2 score on a scale
Standard Deviation 2.3
|
|
Numeric Pain Rating Scale - Cohort 5
Low Energy 2, cycling off (Period 4)
|
4.2 score on a scale
Standard Deviation 2.0
|
|
Numeric Pain Rating Scale - Cohort 5
Low Energy 2, cycling ON (Period 5)
|
4.7 score on a scale
Standard Deviation 2.2
|
|
Numeric Pain Rating Scale - Cohort 5
Low Energy 2, cycling ON (Period 6)
|
4.5 score on a scale
Standard Deviation 1.8
|
PRIMARY outcome
Timeframe: Up to 7 monthsPopulation: Number analyzed refers to patients with measure available.
To characterize the effect of different programmed settings on pain relief. The NPRS will be recorded once or daily over a period of time, where the subjects will rate their pain on a 11-point numeric rating scale of 0 to 10, with 0 representing 'No Pain' and 10 representing 'Worst pain imaginable'. The average overall NPRS pain score prior to the scheduled visit will be used for analysis.
Outcome measures
| Measure |
Cohort 1: Low Energy - Continuous Initial
n=22 Participants
Subjects will be programmed to a specific frequency with a long pulse width at various amplitudes
Spinal Cord Stimulation: Programming
|
|---|---|
|
Numeric Pain Rating Scale (NPRS) - Cohort 6
Enrollment
|
3.5 score on a scale
Standard Deviation 1.8
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 6
Washout (Follow-up 1)
|
5.6 score on a scale
Standard Deviation 2.0
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 6
DTM-LE Continuous (Follow-up 2)
|
4.3 score on a scale
Standard Deviation 2.1
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 6
DTM-LE Duty Cycle Enabled* (Follow-up 3)
|
4.4 score on a scale
Standard Deviation 2.1
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 6
2-Week Follow-up (Follow-up 4)
|
3.7 score on a scale
Standard Deviation 1.6
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 6
1-Month Follow-up (Follow-up 5)
|
3.8 score on a scale
Standard Deviation 1.7
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 6
2-Month Follow-up (Follow-up 6)
|
4.2 score on a scale
Standard Deviation 1.1
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 6
3-Month Follow-up (Final Study Visit)
|
4.0 score on a scale
Standard Deviation 1.4
|
PRIMARY outcome
Timeframe: Up to 8 monthsPopulation: Number analyzed refers to patients with measure available.
To characterize the effect of different programmed settings on pain relief. The NPRS will be recorded once or daily over a period of time, where the subjects will rate their pain on a 11-point numeric rating scale of 0 to 10, with 0 representing 'No Pain' and 10 representing 'Worst pain imaginable'. The average overall NPRS pain score prior to the scheduled visit will be used for analysis.
Outcome measures
| Measure |
Cohort 1: Low Energy - Continuous Initial
n=17 Participants
Subjects will be programmed to a specific frequency with a long pulse width at various amplitudes
Spinal Cord Stimulation: Programming
|
|---|---|
|
Numeric Pain Rating Scale (NPRS) - Cohort 7
1-Month Post Titration Phase (Follow Up 8)
|
3.3 score on a scale
Standard Deviation 2.1
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 7
2-Months Post Titration Phase (Follow Up 9)
|
4.3 score on a scale
Standard Deviation 3.1
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 7
3-Months Post Titration Phase (Final Study Visit)
|
3.0 score on a scale
Standard Deviation 3.1
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 7
Pre-SCS Pain Score
|
8.5 score on a scale
Standard Deviation 1.4
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 7
Enrollment
|
5.5 score on a scale
Standard Deviation 3.0
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 7
Optimization Visit 1 (Follow Up 1)
|
6.1 score on a scale
Standard Deviation 2.2
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 7
Optimization Visit 2 (Follow Up 2)
|
5.2 score on a scale
Standard Deviation 2.2
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 7
Optimization Visit 3 (Follow Up 3)
|
4.2 score on a scale
Standard Deviation 2.0
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 7
Start of Titration Phase (Follow Up 4)
|
4.0 score on a scale
Standard Deviation 2.0
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 7
2-Week Titration Phase (Follow Up 5)
|
4.6 score on a scale
Standard Deviation 2.3
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 7
4-Week Titration Phase (Follow Up 6)
|
3.6 score on a scale
Standard Deviation 2.3
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 7
End of Titration Phase (Follow Up 7)
|
3.2 score on a scale
Standard Deviation 1.7
|
PRIMARY outcome
Timeframe: Up to 0.5 monthsPopulation: Number analyzed refers to patients with measure available.
To characterize the effect of different programmed settings on pain relief. The NPRS will be recorded once or daily over a period of time, where the subjects will rate their pain on a 11-point numeric rating scale of 0 to 10, with 0 representing 'No Pain' and 10 representing 'Worst pain imaginable'. The average overall NPRS pain score prior to the scheduled visit will be used for analysis.
Outcome measures
| Measure |
Cohort 1: Low Energy - Continuous Initial
n=4 Participants
Subjects will be programmed to a specific frequency with a long pulse width at various amplitudes
Spinal Cord Stimulation: Programming
|
|---|---|
|
Numeric Pain Rating Scale (NPRS) - Cohort 8
Enrollment
|
3 score on a scale
Standard Deviation 1.83
|
|
Numeric Pain Rating Scale (NPRS) - Cohort 8
Final Study Visit
|
3.25 score on a scale
Standard Deviation 2.22
|
PRIMARY outcome
Timeframe: Up to 1 monthPopulation: Number analyzed refers to patients with measure available.
To characterize the effect of different programmed settings on pain relief. The NPRS will be recorded once or daily over a period of time, where the subjects will rate their pain on a 11-point numeric rating scale of 0 to 10, with 0 representing 'No Pain' and 10 representing 'Worst pain imaginable'. The average overall NPRS pain score prior to the scheduled visit will be used for analysis.
Outcome measures
| Measure |
Cohort 1: Low Energy - Continuous Initial
n=10 Participants
Subjects will be programmed to a specific frequency with a long pulse width at various amplitudes
Spinal Cord Stimulation: Programming
|
|---|---|
|
Numeric Pain Rating Scale at Enrollment (NPRS) - Cohort 9
|
3.8 score on a scale
Standard Deviation 2.25
|
Adverse Events
Cohort 1: Low Energy - Continuous
Serious events: 0 serious events
Other events: 5 other events
Deaths: 0 deaths
Cohort 2: Interleaving
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
Cohort 3: Cycling Evolve
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Cohort 4: Low Energy Cycling 1
Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths
Cohort 5: Low Energy Cycling 2
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS)
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
Cohort 7: Super Cycle
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
Cohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS)
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Cohort 1: Low Energy - Continuous
n=15 participants at risk
Subjects will be programmed to a specific frequency with a long pulse width at various amplitudes
Spinal Cord Stimulation: Programming
|
Cohort 2: Interleaving
n=10 participants at risk
Determine effects of delivering ping pulses combined with governed pulses while using separate sets of electrodes
Spinal Cord Stimulation: Programming
|
Cohort 3: Cycling Evolve
n=4 participants at risk
Subjects will be programmed to high dose (HD) stimulation with various cycling parameters
Spinal Cord Stimulation: Programming
|
Cohort 4: Low Energy Cycling 1
n=15 participants at risk
Effects of decreased pulse widths with increased frequency - with and without cycling parameters
Spinal Cord Stimulation: Programming
|
Cohort 5: Low Energy Cycling 2
n=15 participants at risk
Effects of decreased pulse widths with increased frequency - with and without cycling parameters (different pulse widths and frequencies than Cohort 4)
Spinal Cord Stimulation: Programming
|
Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS)
n=22 participants at risk
Effects of decreased frequency and therapy cycling parameters Spinal Cord Stimulation: Programming
|
Cohort 7: Super Cycle
n=17 participants at risk
Effects of longer cycle duration
Spinal Cord Stimulation: Programming
|
Cohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS)
n=4 participants at risk
Effects of integrating Neuro Sense into DTM programming
Spinal Cord Stimulation: Programming
|
Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow
n=11 participants at risk
Characteristics of vital signs in DPN participants
Spinal Cord Stimulation: Programming
|
|---|---|---|---|---|---|---|---|---|---|
|
Nervous system disorders
Sciatica
|
6.7%
1/15 • Number of events 1 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/10 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/4 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/15 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/15 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/22 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/17 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/4 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/11 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
|
Musculoskeletal and connective tissue disorders
Groin pain
|
6.7%
1/15 • Number of events 1 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/10 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/4 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/15 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/15 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/22 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/17 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/4 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/11 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
|
General disorders
Pain
|
20.0%
3/15 • Number of events 3 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/10 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/4 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/15 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/15 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/22 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/17 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/4 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/11 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
|
Nervous system disorders
Neuralgia
|
0.00%
0/15 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
10.0%
1/10 • Number of events 1 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/4 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/15 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/15 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/22 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/17 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/4 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/11 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/15 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/10 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/4 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
6.7%
1/15 • Number of events 1 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/15 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
4.5%
1/22 • Number of events 1 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/17 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/4 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/11 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
|
Product Issues
Device stimulation issue
|
0.00%
0/15 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/10 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/4 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
20.0%
3/15 • Number of events 4 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
13.3%
2/15 • Number of events 2 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/22 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/17 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/4 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/11 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
0.00%
0/15 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/10 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/4 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/15 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/15 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
4.5%
1/22 • Number of events 1 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/17 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/4 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/11 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
|
Nervous system disorders
Headache
|
0.00%
0/15 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/10 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/4 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/15 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/15 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
4.5%
1/22 • Number of events 1 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/17 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/4 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/11 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/15 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/10 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/4 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/15 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/15 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/22 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
5.9%
1/17 • Number of events 1 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/4 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/11 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
|
General disorders
Medical device site irritation
|
0.00%
0/15 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/10 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/4 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/15 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/15 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/22 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
5.9%
1/17 • Number of events 1 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/4 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/11 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
|
General disorders
Medical device site pain
|
0.00%
0/15 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/10 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/4 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/15 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/15 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/22 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
5.9%
1/17 • Number of events 1 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/4 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
0.00%
0/11 • Cohort 1: 4.4 months Cohort 2: 1.5 months Cohort 3: 3.0 months Cohort 4: 2.1 months Cohort 5: 2.8 months Cohort 6: 6.8 months Cohort 7: 7.8 months Cohort 8: 0.5 months Cohort 9: 0.6 months
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place